Saratoga Investment Corp. NT 23

Eröffnung

25,63

Vortag

25,65

Tagesspanne

25,62 – 25,74

52 Wochen

25,62 – 211.000

Volumen

3003

Ø Volumen

69.915

Börsenwert

150,76 Mio. $

KGV

–

Gewinn je Aktie (TTM)

–

Dividendenrendite

–

Beta

0,0

Nächste Zahlen

–

Gerade nicht verfügbar.

• BCICBCP Investment Corporation6,625+0,84 %
• BCSABlockchain Coinvestors Acquisition Corp. I11,58–
• CCAPCrescent Capital BDC, Inc.9,815+6,22 %
• DMFBNY Mellon Municipal Income, Inc.6,98+0,72 %
• FNCBFNCB Bancorp, Inc.6,75+5,30 %
• LCWLearn CW Investment Corporation10,87−7,09 %
• OXSQOxford Square Capital Corp.0,8211−0,27 %
• SALSalisbury Bancorp, Inc.27,88+1,57 %

• GlobeNewsWire · 5. Nov., 7:30SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
• GlobeNewsWire · 29. Okt., 8:30SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
• GlobeNewsWire · 29. Okt., 8:30Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
• MarketBeat · 23. Okt., 1:02SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
• GlobeNewsWire · 22. Okt., 8:30Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
• GlobeNewsWire · 14. Okt., 8:30SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
• GlobeNewsWire · 13. Okt., 8:30SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
• GlobeNewsWire · 1. Okt., 8:30SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
• GlobeNewsWire · 22. Sept., 8:30SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
• GlobeNewsWire · 1. Sept., 8:30SAB BIO to Participate in Upcoming Investor Conferences